GSK plc Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before April 7, 2025 to Discuss Your Rights - GSK

Core Viewpoint - GSK plc is facing a class action lawsuit related to the alleged misleading statements regarding the withdrawal of Zantac from the market and the company's knowledge of the potential cancer-causing agent NDMA [1][2]. Group 1: Allegations and Class Period - The class period for the lawsuit is from February 5, 2020, to August 14, 2022 [1]. - Allegations include that GSK misrepresented the reasons for removing Zantac, claiming it was based on available information and regulatory correspondence, while being aware of the NDMA source for nearly 40 years [1]. Group 2: Shareholder Actions - Shareholders who purchased GSK shares during the specified period are encouraged to register for the class action and can seek lead plaintiff status by April 7, 2025 [2]. - Registered shareholders will receive updates through portfolio monitoring software regarding the case's progress [2]. Group 3: Law Firm's Mission - The Gross Law Firm aims to protect investors' rights against deceit and fraud, ensuring companies adhere to responsible business practices [3].